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This study assessed whether or not the initial drugs and routes of administrations of 
people who inject drugs (PWID) in Baltimore have changed over time.  With over 2 
million PWID in North America, injection drug use is an important public health 
problem.  Recent studies suggest that the pathway towards injection drug use is changing, 
with younger PWID having first abused prescription opioids rather than non-injected 
cocaine or heroin, which has been the traditional pathway.  In this study we characterized 
1,005 participants of the AIDS Linked to the IntraVenous Experience (ALIVE) study, a 
community-based cohort of current and former PWID in Baltimore. We identified three 
distinct patterns of drug use initiation: those who initiated directly with injection drugs, 
those who initiated drug use with non-injected cocaine or heroin, and those who initiated 
with prescription opioid use.  Of the 1005 participants, 211 (21%) initiated drug use with 
prescription opioid pills, 605 (60%) initiated with non-injected cocaine or heroin, and 189 
(19%) directly with injection drug use (56% with heroin, 28% with cocaine and 16% with 
a combination of cocaine and heroin).  Demographic and risk behaviors were compared 
across drug initiation groups. Participants 33 years of age were significantly more likely 
to have initiated with non-injected cocaine or heroin, or directly with injection drug use, 
while younger participants (25 years of age) were more likely to initiate with prescription 
pills obtained on the street. While time to injection drug use initiation was not 
significantly different across groups, participants who initiated with prescription opioid 
use differed with respect to other factors.  Participants who initiated drug use with 
prescription drugs were mostly white, younger than those who initiated via injected drug 





initiated via non-injected cocaine or heroin.  One limitation of this study is that as we 
only observed PWID, there may be people abusing prescription opioids who do not 
transition to injection drug use.  Future studies should observe this transition more 
closely, and physicians and public health practitioners should be aware of these changing 
trends in injection drug use initiation. 
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  Injection drug use is commonly associated with an increased risk or morbidity and 
mortality.
1
  There are approximately 16 million PWID worldwide, 3 million of whom are 
estimated to be HIV infected.
2
  Moreover, the sharing of unsterilized needles and other 
paraphernalia used for injection drug use can lead to the transmission of other blood 
borne pathogens such hepatitis B virus (HBV) and hepatitis C virus (HCV) infection, 
which like HIV can result in chronic disease.
1
  HIV, in particular, is notable in that 
approximately 30 percent of global HIV infections outside of sub-Saharan Africa are the 
result of injection drug use.
2
  Hepatitis C is notable because it is estimated to be ten times 
more infectious than HIV and affects up to 80% of PWID and 90% of HIV-infected 
PWID.
3,4
  Because HIV is also sexually transmitted, and there tends to be overlap 
between PWID and their sexual partners, injection drug use can serve as a mechanism for 
further spread of the virus into at-risk populations.  Harm reduction strategies including 
opiate substitution therapy and needle exchange programs have been shown to decrease 
the transmission of blood borne pathogens, particularly HIV, among PWID.
2
   
Generally, PWID do not initiate drug use with injection.  There is more often a 
pathway towards injection drug use that starts with other substance use, typically by a 
non-injection route.  In prior studies, the trend has been observed as moving from non 
injection heroin or cocaine use to injection of heroin and/or cocaine.
5,6
  Several risk 
factors for transitions into injection drug use have been identified among those using 
other drugs including race other than African American, male sex, early drug initiation, 
and early alcohol and cigarette initiation.
6
In North American there are approximately 2.3 







have been reports of a shift in the epidemiology of drug use in the US. In particular, there 
has been an increase in prescription drug use that has been increasingly reported outside 
of urban settings
7
.  In some settings prescription drugs are being injected and in others 
transitions to injection of other drugs has been reported and has been associated with high 
rates of hepatitis C virus and other morbidity
8
.    
Adolescents who inject drugs have distinct risk considerations from older PWID, 
making it crucial to consider these differences in analysis rather than grouping all PWID 
together.  In particular, adolescent PWID often have a shorter duration of drug use before 
injection initiation than older PWID.  Moreover, studies have found that homelessness as 
well as exclusive crack smoking prior to initiation and marijuana use have been 
associated with an increased risk of transitions into injection drug use in adolescents.
9,10
  
Among drugs which are injected, most adolescents first inject heroin alone before other 
injection drugs, and generally have inhaled cocaine or heroin before beginning to inject.
1
   
As younger people are more likely to exhibit high risk behaviors, such as needle sharing, 
HIV transmission is of concern for this group.
11
  Recent studies have found that younger 
PWID are more frequently initiating drug use with prescription opioid misuse before 
transitioning into other illicit drugs and, eventually, injected drugs.
12,13
  Observing 
changes in how younger participants are initiating injection drug use is valuable 
information for public health endeavors.  Efforts should be made to understand changes 
in drug initiation patterns in order to design intervention techniques that are up to date 
with the current trends. 
Baltimore has an estimated 336 PWID per 10,000 people aged 15-64, making it 







Moreover, death rates in Baltimore City in 2012 for heroin use was 20 per 100,000 
people, while death by prescription opioid use was 10 per 100,000 people.
15
  Historically, 
the most common drugs of abuse have included heroin, cocaine and crack. The goal of 
this analysis was to explore changes in drug initiation pathways over time, as well as 




The ALIVE (AIDS Linked to the IntraVenous Experience) Study is a longitudinal 
community based cohort of current and former PWID in Baltimore, Maryland as 
previously described
16
.  The ALIVE study was originally designed to study the 
progression and management of HIV in PWID, but now also assesses common co-
infections (such as Hepatitis C) and the impact of highly active antiretroviral therapy 
(HAART).  Participants in the ALIVE study are followed semi-annually, where clinical, 
laboratory, and behavioral data are collected.  Recruitment for the ALIVE study was 
originally conducted between 1988-89, and has since again opened up in waves in 1994-
95, 1998, and from 2005-2008.  In order to be eligible for the ALIVE study, participants 
needed to be at least 18 years of age, HIV negative, and have a baseline history of 
injection drug use.  Until the 2005-2008 recruitment cycle, participants were not asked 
specifically about illicit prescription drug use.  This analysis was conducted among the 
1005 participants who enrolled in 2005-2008. Inclusion criteria for this analysis included 
the availability of drug initiation category data and enrollment in the ALIVE study 






For the ALIVE study, during baseline visits, surveys are used to collect data on 
lifetime and recent risk behavior, baseline status of education, income, employment, and 
lifetime history of drug use.  During semiannual study visits, demographic and social 
factors are evaluated, including frequency, route and types of drugs injected, medical 
history, HIV risk behaviors, and drug treatment.  Moreover, participants are counseled, 
assisted in finding social services for which they qualify, and given information of other 
studies they may be eligible for.  Laboratory results, including HIV and HCV antibody 
tests, HIV viral loads, and CD4 T-cell counts are obtained via blood draw.   
Statistical Analysis 
Participants were classified into one of three groups according to the first drug 
that they reported using other than alcohol or marijuana as well as the route of 
administration. The first group included those that reported no non-injection drug use 
prior to injection (injection first). The second group included those that reported non-
injection cocaine (including crack) and/or heroin as their first drug (non-injection 
cocaine/heroin) and the third group included those that started with some sort of 
prescription drug (prescription drugs). The latter group included persons who reported 
starting drug use with any of the following drugs purchased on the street: oxycontin, 
buprenorphine, percocet, benzodiazepines or clonidine.  We first compared these three 
groups with respect to demographic characteristics and risk behaviors using Pearson chi-
square.  
A retrospective time-to-event survival analysis was conducted in order to 





injection, the time to injection initiation differed by drug of first use.  Here, the time 
metric used was years, and entry was defined as the age of the participant at the time of 
first non-injection drug use (other than marijuana or alcohol use).  All persons had the 
outcome of interest as all persons in this analysis had injected drugs prior to enrolling in 
the study. Persons were considered to have the event at their self-reported age of first 
injection drug use.  This analysis included 816 participants (all participants excluding 
those who initiated drug use with injection drugs).  There were 236 participants who 
began injecting drugs within the year of their first drug use.  These participants were 
coded as contributing six months of person time.  Survival analyses included Kaplan-
Meier survival curves with a log-rank test and Cox regression analysis to adjust for 




Characteristics of study participants (N=1,005) are summarized in Table 1.  Of the 
total sample, 189 (19%) initiated drug use with a drug that was injected (56% with 
heroin, 28% with cocaine and 16% with a combination of cocaine and heroin).  605 
(60%) initiated with non-injection cocaine or heroin and 211 (21%) initiated drug use 
with prescription drugs obtained on the street.  Overall, the mean age of initiation of drug 
use was similar across the three groups.  While a majority of participants who initiated 
drug use with either injection drugs or with non-injected cocaine or heroin were black, 
this demographic accounted for only 37% of participants who initiated with prescription 





less likely to have a high school education at baseline than those who initiated with non-
injection drug use, as well as a higher prevalence of HIV and HCV (p<0.05 for all).  All 
three groups had similar average ages of alcohol and cigarette initiation, however the 
group that initiated with injection drugs had a slightly higher average age of marijuana 
initiation, but this difference was not statistically significant. 
Risk behaviors  
Drug initiation groups were also compared with respect to other risk behaviors 
reported.   Statistically significant differences between the three groups were found in 
drug use, homelessness, incarceration, and HIV and HCV prevalence.  Participants who 
initiated with pills were significantly less likely to have ever been in prison than those 
who initiated with injected drugs or those who initiated with non-injected cocaine or 
heroin (p<0.001). Compared to the group that initiated with injection drugs, the group 
that initiated drug use with prescription drugs had a higher prevalence methamphetamine 
use (p=<0.001). The group that initiated with injection drugs, however, reported higher 
prevalence of prior speedball injection. This information is summarized in Tables 2 and 
3. 
Persons < age 33 were significantly more likely to have initiated drug use with a 
prescription pill than older age ranges.  Time to initiation of injection drug use was not 
significantly between the non-injected cocaine/heroin and pills drug initiation groups 
(p=0.246), however, participants who initiated with prescription pill use differed with 
respect to other factors.  Participants in the pill group were significantly more likely to be 





and incarceration and a higher prevalence of crystal meth use.  This information is 
summarized in Tables 2 and 3. 
Injection Drug Initiation Pathways 
We explored patterns in injection drug initiation pathways by using current age as 
a proxy for time. The oldest participants (age 48 and higher) had the largest prevalence of 
drug initiation with an injected drug followed by non-injection cocaine/heroin use, while 
younger participants (under age 25) were significantly more likely to initiate with 
prescription pills obtained on the streets.  Participants were separated into age categories 
in six year intervals for participants aged 36 and up, and four year intervals for those aged 
35 and below.  Current age was strongly associated with drug initiation group.  Among 
those under age 25, 60% initiated with prescription drugs, 35% with non-injection 
cocaine or heroin, and 5% with injection drug use.  Of the participants aged 33-35, 19% 
initiated with prescription drugs, 72% initiated with non-injection cocaine or heroin, and 
9% with an injected drug.  In contrast, among participants age 48 or older, 15% initiated 
with prescription drugs, 51% with non-injection cocaine or heroin, and 34% with 
injection drug use.  This data is summarized in Figure 1.   
Trends in transition to injection drug initiation 
Participants who initiated drug use with prescription opioids appeared to have a 
longer time between the initiation of drug use and the initiation of injected drugs 
compared to those who initiated drug use with non-injection cocaine/heroin; however 
these differences were not statistically significant.  These results are displayed in Figure 





Further time to event analysis for time from drug initiation to injected drug 
initiation revealed that the time to initiation of injection was the same in both groups 
(unadjusted p-value = 0.343). There was no difference between the two groups even after 
adjusting for other factors associated with time to injection initiation including age, race, 
sex, ages of cigarette, alcohol, and marijuana initiation, employment, and high school 
education (adjusted relative hazard: 0.936; 95% confidence interval: 0.773-1.134).  
Among these, the only significant result was found for initiating injection drug use at an 
early age (p-value = 0.000).  Notably, there was still no notable effect on hazard ratio for 
injection drug initiation comparing those who initiate with pills versus those who initiate 
with prescription opioid abuse (Hazard ratio = 1.09, p-value = 0.404).  Sensitivity 
analysis, in which time was treated as a continuous variable using linear regression, also 
showed no difference between the groups. 
 
Discussion:  
We observed a trend in which younger PWID in Baltimore tended towards 
initiating drug use with prescription drug use.
12,13
 While older injectors (aged 36 and up) 
in this sample tended to initiate drug use with cocaine and/or heroin by injection or non-
injection, there was a trend for younger drug users (aged 28 and below) to initiate 
injection with prescription drugs purchased on the street. This younger group has a 
different profile with respect to race, sex and other risk behaviors than their older 
counterparts. Despite this difference in initiation pathway, the time from drug initiation to 





Moreover, groups varied with respect to certain demographic and drug use 
characteristics. 
Injection drug use is a widespread public health problem, particularly in 
Baltimore, that contributes to the spread of HIV as well as HCV infection.
5
  Due to the 
large prevalence of injection drug use, it is crucial to aim interventions at preventing 
injection drug use initiation.  While previous studies have shown non-injected 
cocaine/heroin use to be predictive of injection drug initiation
6
, more recent studies have 
suggested that prescription opioid misuse is becoming an increasingly common pathway 
to injection drug initiation. This analysis provides further evidence of this new pathway 
among younger participants.  It was interesting that initiating drug use with prescription 
drugs as opposed to cocaine or heroin did not seem to alter the time to first drug injection.  
While there was low sample size in the younger age groups, the trend was consistent 
across all those below 35 years of age.    
While similar in many respects, there are some notable differences between these 
groups.  Participants who initiated drug use with opioid pill abuse were more likely to be 
employed at baseline, much more likely to be white, and had a lower Hepatitis C 
prevalence at baseline.  This group also had a much higher prevalence of crystal meth 
use, which may reflect either a surge in recent crystal meth use, or demographic and 
social differences between participants who initiated in this manner and participants who 
initiated with non-injected cocaine or heroin. 
Survival analysis did not demonstrate any significant difference in time to 
injection drug initiation between the groups who initiated drug use with non-injected 





(p-value = 0.776), cigarette use (p-value = 0.728), nor marijuana use (p-value = 0.533) 
had statistically significant impact on the hazard ratio for time to injection drug use 
comparing those who initiated drug use with pills versus those who initiated with non-
injected cocaine or heroin.  Sex, race, education, employment, and drug initiation group 
were not predictive of differences in time to injection drug use.  After controlling for a 
variety of cofactors, the only item which appeared predictive of a shorter time to first 
injection drug use was a participant being under age 25.  Sensitivity analysis for time to 
injection drug use demonstrated a statistically significant increase in time to injection 
drug use; however this is likely due to the increased average age of marijuana initiation in 
the group which initiated drug use with injection drugs (p=0.023). 
 Some limitations of this study include the fact that it is based on the results of a 
single study site, and is thus limited to the population of the Baltimore area.  This may 
affect the generalizability of the study as the urban, predominantly African American 
Baltimore population may not be representative of other parts of the country with 
different demographics and social trends.  Additionally, this analysis was heavily reliant 
on self reported drug use data, and is subject to recall bias.  Moreover, we did not sample 
pill users and then identify which among them transitioned into injection drug use; rather 
in this secondary data analysis we observed PWID and retrospectively determined who 
initiated drug use with prescription opioid abuse.  There may be many others who initiate 
drug abuse in this manner who do not transition into injection drug use. Further studies 
should observe a large cohort of participants who abuse prescription drugs, and then 







While there was no significant difference in the time to first  injection drug use by 
drug initiation category, participants who initiated drug use with prescription opioid pills 
have a distinct set of risk factors and demographic characteristics from those of the other 
two drug initiation pathways.  A majority of these participants are younger, white, and 
have a decreased prevalence of HIV, HCV, and prison time.  The HIV and HCV 
prevalence are partially attributable to being a younger cohort of participants, who have 
had less time than the other two groups to acquire a blood borne pathogen.  However, 
despite this being a younger cohort, these participants also have an increased prevalence 
of crystal meth use.   
Care should be taken when designing public health interventions to consider these 
changes in injection drug use initiation to better capture the modern audience.  As studies 
continue to observe young patients transitioning into injection drug use from prescription 
opioid abuse, this rising drug initiation pathway should be considered by physicians and 
public health practitioners alike.  While there are still significant amounts of new PWID 
who initiated drug use with non-injected cocaine or heroin, the growing cohort of those 
abusing prescription opioids and then transitioning to injection drug use need be 
considered.  Future studies should observe this cohort more closely to determine points at 








Tables and Figures: 
 
Table 1 – Demographic Data  
Drug Initiation Group  Pills  
Non-Injected 
Cocaine/Heroin  
Injection Drugs  
N  211  605  189  
Mean age (SD)  38.11 (10.33)  41.95 (8.57)  48.1 (7.30)  
Mean age of drug use initiation (SD)  17.8 (5.16)  19.2 (5.73)  18.1 (4.88)  
Mean age of Injection Drug Use 
Initiation (SD)  
22.7 (7.07)  23.6 (7.79)  18.1 (4.88)  
Sex  
     Men  
     Women  
146 (69.19%)  
65 (30.81%)  
363 (60%)  
242 (40%)  
143 (75.66%)  
46 (24.34%)  
Race  
     White  
     Black  
132 (62.56%)  
79 (37.44%)  
182 (30.08%)  
423 (69.92%)  
21 (11.11%)  
168 (88.89%)  
High School Education at Baseline  96 (45.5%)  269 (44.46%)  67 (35.45%)  
Currently employed  27 (12.80%)  44 (7.28%)  12 (6.38%)  
Income <$5000  168 (80.77%)  470 (78.73%)  143 (77.30%)  
Baseline HIV Prevalence  36 (18.18%)  175 (30.7%)  67 (37.43%)  








Figure 1 - Drug Initiation by Age Range 
Table 2 – Demographic Differences Between Pill and Non-Injected Cocaine/Heroin Groups  




Mean age (SD)  38.1 (10.3)  41.95 (8.57)  <0.001  
Mean age of drug use initiation (SD)  14.6 (3.73)  15.03 (3.71)  0.122  
Mean age of non-marijuana drug use 
initiation (SD)  
17.8 (5.16)  19.2 (5.73)  0.002  
Mean age of Injection Drug Use 
Initiation (SD)  
22.7 (7.07)  23.6 (7.79)  0.133  
Time from First non-marijuana Drug 
Use to Injection Drug Use (SD)  
5.68 (6.22)  5.11 (6.03)  0.246  
Sex  
     Men  
     Women  
146 (69.19%)  
65 (30.81%)  
363 (60%)  
242 (40%)  
0.018  
Race  
     White  
     Black  
132 (62.56%)  
79 (37.44%)  
182 (30.08%)  
423 (69.92%)  
<0.001  
Baseline High School Education  96 (45.5%)  269 (44.46%)  0.795  
Currently employed  27 (12.80%)  44 (7.28%)  0.015  
Income <$5000  168 (80.77%)  470 (78.73%)  0.532  
Baseline HIV Prevalence  36 (18.18%)  175 (30.7%)  0.001  





Table 3 – Risk Factor Differences Between Pill and Non-Injected Cocaine/Heroin Groups  




Ever attended a shooting gallery  
     Yes  
     No  
185 (87.68%)  
26 (12.32%)  
513 (84.79%)  
92 (15.21%)  
0.305  
Ever been incarcerated  
     Yes  
     No 
95 (45.02%)  
116 (54.98%)  
337 (55.70%)  
268 (44.30%)  
0.007  
Ever used crack  
     Yes  
     No 
200 (94.79%)  
11 (5.21%)  
553 (91.40%)  
52 (8.60%)  
0.113  
Ever used crystal meth  
     Yes  
     No 
56 (26.54%)  
155 (73.46%)  
87 (14.40%)  
518 (85.62%)  
<0.001  
Ever used speedball  
     Yes  
     No 
178 (84.36%)  
33 (15.64%)  
508 (83.97%)  
97 (16.03%)  
0.893  
Ever been homeless  
     Yes  
     No 
180 (86.12%)  
31 (14.69%)  
488 (80.66%)  
117 (19.34%)  
0.076  
Ever tested for HIV  
     Yes  
     No 
200 (94.79%)  
11 (5.21%)  
586 (97.34%)  
19 (3.14%)  
0.075  
Injected drugs in last 6 months  
     Yes  
     No 
194 (91.94%)  
17 (8.06%)  
538 (88.93%)  
67 (11.07%)  
0.214  
Ever undergone drug treatment  
     Yes  
     No 
190 (90.05%)  
21 (9.95%)  
532 (88.08%)  
73 (12.07%)  
0.439  
Mean Age of Alcohol Initiation 
(SD)  
13.8 (4.26)  14.1 (4.16)  0.526  
Mean Age of Cigarette Initiation 
(SD)  
14 (6.13)  14.4 (5.35)  0.366  
Mean Age of Marijuana Initiation 
(SD)  







































Figure 3 - Kaplan Meier Survival Curve comparing participants who initiated with pills compared to those who 
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Responsible for maintaining, collecting, verifying, and updating the pediatric clinical data that Johns Hopkins 
Hospital submits to the HIVRN.  Additionally, identify and consent clinic patients to enroll into the IMPAACT 









Hopkins Emergency Response Unit.  Reserve Crew Chief.  The Johns Hopkins University. Fall 2012 – May 2015.   
The Hopkins Emergency Response Organization (HERO) provides the Johns Hopkins Homewood Campus and 
surrounding areas with 24/7, quality emergency medical care.  As a Reserve Crew Chief, I take 3 on-call eight 
hour shifts per week and hold the main authority on scene, including treatment and transport decisions of patients 
as well as overseeing crew members and Crew Chiefs.  
 
South Miami Hospital Emergency Department. Medical Scribe. Miami, FL Summer 2012 – May 2015.  Seasonal. 
Accompany physicians into examination rooms and document patients’ symptoms, physical examination, vital 
signs, and lab values.  Additionally, I look up pertinent past medical records, keep track of and enter results of 
imaging studies, log progress notes, and document discharge plan including prescriptions. 
 
R. Adams Cowley Shock Trauma Center. Clinical Observation Program. Baltimore, MD.  Fall 2011, Spring 2013 
Participated in the Trauma Resuscitation Unit to examine the hospital course and treatment of trauma patients, 
and assisted with physical assessments.  Followed patients from arrival to the operating room, translating 
English/Spanish when needed, went on hospital rounds, observed surgeries and clinical interactions. 
 
Community Service/Volunteer - Medical/Clinical 
Johns Hopkins Bayview Medical Center.  Health Leads Baltimore.  Patient Advocate. Spanish Interpreter.   
Fall 2010 - Spring 2014.  (Formerly Project Health) 
Health Leads is a national organization dedicated to assisting underprivileged patients by connecting them to 
public resources. I work directly with patients to assess and prioritize what resources exist to meet their needs, 
and determine the best course of action for that client by searching for resources for which they qualify.  Often, 
cases require follow up with both the client and the Department of Social Services and consistent contact with 
clients until the case is closed.  Have gained experience and insight into healthcare and social services network as 
well as multitasking, communication, and organizational skills.  Official Spanish interpreter for the hospital as of 
fall 2012. 
 
Hopkins Emergency Response Teaching Unit (HERTU). S5, Recruitment, Special Projects and Public Affairs 
Officer.  Spring 2012 - Fall 2012.  Operations and Planning Chair.  Fall 2011 - Spring 2012.  Instructor.  Fall 
2011 - Spring 2013.  Teaching Assistant. Fall 2010 - Fall 2011. 
HERTU, a sister organization to the aforementioned HERU, aimed to train new HERU unit members in 
accordance with the American Red Cross Emergency Medical Response (EMR) curriculum, as well as provide 
community CPR/AED certification courses out of the Johns Hopkins Homewood campus.  Led and organized 
lectures, while evaluating presentations by TAs and answering student’s questions.  Ran practices scenarios while 
giving constructive feedback to students.  Ran EMR as well as CPR/AED certification courses and exams.  As 
Operations and Planning Chair, scheduled and prepared lesson plans while maintaining the flow of day to day 
activities.  As S5, recruited students into both the EMR and community CPR/AED courses.  Responsible for 
organizing the courses, team building activities and events. 
 
Miami-Dade Fire Department. Ride Alongs. Air Rescue.  Summer 2012.  Ambulance. Summer 2011.  
 
Baltimore Eastern Clinic (Baltimore Department of Health). Interpreter (English/Spanish.) Fall 2010. 
Simultaneous translation between patients and health providers, including extensive use of medical terminology.  
Worked primarily in the Sexually Transmitted Diseases’ Clinic and the Oncology department.  Volunteer work 











Adrian Cotarelo, Homaira Zaman, Lois Jovanovič, MD, Moshe Hod, MD.  Advanced Technologies and 
Treatments in Diabetes 2013 Yearbook, Chapter 8: Technology and Pregnancy. The Advanced Technologies and 
Treatments in Diabetes (ATTD) Yearbook is a review of the most current, groundbreaking research in the field of 
diabetes management and prevention.  Also available as an online journal supplement and indexed/abstracted in 
MEDLINE, PubMed, and other databases. 
 
Adrian Cotarelo, Nancy Hutton, MD, FAAP, and Allison Agwu, MD, ScM, FAAP.  The Unfortunate 
Disconnect: Profoundly Immunosuppressed Vertically Infected HIV Patients with Poor Understanding of 
Morbidity and Mortality.  Poster presented at the Pediatric Academic Societies’ Annual Meeting in Washington, 
DC.  May 2013. 
Oral presentation at the 5
th
 Annual Undergraduate Conference in Public Health at Johns Hopkins University.  
Spring 2014 
 
Adrian Cotarelo.  “Damaging Effects of Irresponsible Media Reporting on the Agricultural Industry.”  3
rd
 Place, 
Future Farmers of America Prepared Speech Division at the Miami-Dade County Northern region competition. 
December 2009. 
 
Adrian Cotarelo.  “Hybridizing Orchids of the Cattleya Alliance.”  Research paper selected for the 2007 Future 
Farmers of America State Conference in Orlando, FL. 
 
Language Fluency  
English (Native) 




Tutoring – Organic Chemistry.  Self-Employed.  Fall 2013 - Present. 
Hopkins Hosting Society.  Volunteer. Spring 2011-Fall 2011. Leadership Board.  Spring 2012 - Fall 2012. 
Hopkins Multicultural Students Association. Volunteer. 
